Liquidia Corp(LQDA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:20 PM ET (Korea 10/31 08:20)
Full metrics table
| Index | RUT | P/E | 33.03 | EPS (ttm) | 1.36 | Insider Own | 13.45% | Shs Outstand | 89.1M | Perf Week | 5.65% |
| Market Cap | 4.03B | Forward P/E | 20.61 | EPS next Y | 7.86% | Insider Trans | -20.17% | Shs Float | 77.5M | Perf Month | 60.99% |
| Enterprise Value | 3.93B | PEG | - | EPS next Q | 0.96 | Inst Own | 79.91% | Short Float | 22.34% | Perf Quarter | -46.26% |
| Income | 0.14B | P/S | 8.94 | EPS this Y | 353.4% | Inst Trans | 14.57% | Short Ratio | 5.19 | Perf Half Y | 18.14% |
| Sales | 0.45B | P/B | 20.58 | EPS next 5Y | - | ROA | 35.57% | Short Interest | 17.30M | Perf YTD | 30.65% |
| Book/sh | 2.19 | P/C | 14.19 | EPS past 3/5Y | -5.98% 14.6% | ROE | 131.82% | 52W High | -51.86% ($93.61) | Perf Year | 94.22% |
| Cash/sh | 3.17 | P/FCF | 26.77 | Sales past 3/5Y | 114.98% 192.49% | ROIC | 42.89% | 52W Low | 102.93% ($22.21) | Perf 3Y | 622.12% |
| Dividend Est. | - | EV/EBITDA | 23.09 | EPS Y/Y TTM | 193.03% | Gross Margin | 92.3% | Volatility(W/M) | 6.08% 8.71% | Perf 5Y | 1101.6% |
| Dividend TTM | - | EV/Sales | 8.72 | Sales Y/Y TTM | 2233.65% | Oper. Margin | 37.39% | ATR (14) | 3.79 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.12 | EPS Q/Q | 251.69% | Profit Margin | 30.74% | RSI (14) | 52.53 | Recom | 1.62 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.31 | Sales Q/Q | 1842.73% | SMA20 | 26.96% ($35.49) | Beta | 0.47 | Target Price | $54.38 |
| Payout | - | Debt/Eq | 0.94 | Earnings | 2026/8/12 | SMA50 | -14.97% ($52.99) | Rel Volume | 0.63 | Prev Close | $44.99 |
| Employees | 216 | LT Debt/Eq | 0.66 | EPS/Sales Surpr. | -0.36% 1.9% | SMA200 | -17.01% ($54.3) | Avg Volume(3M) | 3.33M | Price | $45.06 |
| IPO | 2018/7/26 | Option/Short | Yes/Yes | Trades | 20518 | Volume | 2,091,683 | Change | 0.16% |
A commercial-stage pharmaceutical company that develops and sells treatments for lung diseases, including pulmonary arterial hypertension. The company recently launched an inhaled therapy for pulmonary arterial hypertension and is rapidly growing sales, making it a healthcare stock with proprietary inhaled formulation technology. Its value hinges on sales of its key therapy, expanding prescriptions, and the competitive landscape.
Over the past 1 year, roughly in the middle
52% below its 1-year high.
Traded less than usual. That is 63% of its average volume.
LQDA makes money exceptionally well
Of every $100 in sales, $37.39 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +353.4% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $2,309. Peers typically go for $1,453.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +1101.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Short interest is a burden
22.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #16 of 83 in the industry
Based on market cap of $4B.
FAQ
What kind of company is LQDA?
LQDA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of LQDA?
The market cap of LQDA is approximately $4.0B, ranking 1,529 within its sector.
What is the P/E ratio of LQDA?
LQDA has a P/E ratio of approximately 33.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LQDA?
LQDA has recorded a 52-week high of $93.61 and a low of $22.21.
